Today: 12 April 2026
Subscribe

Hertz Stock Skyrockets on First Profit in 2 Years – What It Means for Investors

Hertz Stock Skyrockets on First Profit in 2 Years – What It Means for Investors

Hertz posted a Q3 2025 net profit of $184 million, its first in nearly two years, compared to a $1.3 billion loss a year ago. Shares jumped up to 27% after earnings beat forecasts, with revenue at $2.5 billion. Fleet upgrades and cost cuts pushed utilization to 84% and slashed depreciation. Hertz scaled back its EV push in 2024, selling 20,000 electric vehicles amid weak rental demand and high costs.
4 November 2025
·
Dave Inc. (DAVE) Stock – Fintech Underdog Turned Wall Street Rocket

Dave Inc. (DAVE) Stock – Fintech Underdog Turned Wall Street Rocket

Dave Inc. stock surged nearly 10% to $264 on November 4 after posting record Q3 revenue of $150.8 million and net income of $92 million. Shares have soared about 500% in the past year, far outpacing the S&P 500. The stock trades near its 52-week high of $286.45, with volatility high and roughly 16% of its float sold short. Most analysts rate DAVE a Buy, with a consensus target of $274.
4 November 2025
·
Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture (SCNX) shares surged 40% to $0.99 pre-market Nov. 4 after its hypertension drug Arbli™ was added to major insurance formularies, expanding coverage to over 100 million people. The company reported just $0.13 million in revenue and a $20 million net loss over the past year. SCNX trades near $0.71, down from a 52-week high of $8.81. Analysts remain cautious, citing high cash burn and uncertain Arbli sales.
4 November 2025
·
Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

Prelude Therapeutics (PRLD) Stock’s Wild Ride: 150% Surge, Big Pharma Deal & What’s Next

Prelude Therapeutics shares surged over 150% on Nov. 3, then dropped about 40% the next day amid record trading. The swings followed news that Incyte Corp. will pay $60 million upfront for rights to Prelude’s JAK2 inhibitor program, with future payments possible. Prelude is pausing one pipeline program, refocusing on two others, and its Chief Medical Officer has departed. Cash reserves now extend operations into 2027.
4 November 2025
··
Ondas Holdings (ONDS) Stock Skyrockets 770% – Huge Deals, Price Swings & 2025 Outlook

Ondas Holdings (ONDS) Stock Skyrockets 770% – Huge Deals, Price Swings & 2025 Outlook

Ondas Holdings (NASDAQ: ONDS) closed at $6.15 on Nov. 3, 2025, after surging above $11 in October and remains up 200% year-to-date. The company announced a deal to acquire Israeli counter-drone firm Sentrycs last week, following several recent defense tech acquisitions. Analysts’ average 1-year price target is $9.50. Shares are in a short-term downtrend, with heavy trading volume and key support near $5.86.
4 November 2025
·
Cipher Mining (CIFR) Rockets on AI Mega-Deals & Bitcoin Boom – What Investors Need to Know

Cipher Mining (CIFR) Rockets on AI Mega-Deals & Bitcoin Boom – What Investors Need to Know

Cipher Mining shares surged 24% to $23 after announcing a $5.5 billion AWS data center deal, lifting its market cap to $9 billion. The company reported Q3 revenue of $71.7 million and a net loss of $0.01 per share, beating forecasts. Cipher also secured an $8.5 billion pipeline of AI hosting contracts and remains a leading Bitcoin miner with 23.6 EH/s deployed.
4 November 2025
····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Bitfarms (BITF) 2025 Stock Surge: Bitcoin Miner’s $500M Windfall & AI Pivot Fuel Rally

Bitfarms (BITF) 2025 Stock Surge: Bitcoin Miner’s $500M Windfall & AI Pivot Fuel Rally

Bitfarms closed a $588 million convertible notes offering on Oct. 21, 2025, to fund expansion. Shares hit a 52-week high of $5.66 in mid-October, up 197% year-over-year, with a market cap near $2.3 billion. Q2 revenue jumped 87% to $78 million, but the company posted a $29 million net loss. Liquidity stood at $230 million in Q2, with a current ratio of 3.1.
4 November 2025
···
Nvidia’s $5 Trillion Milestone: AI Boom Propels NVDA Stock to New Heights

Nvidia’s $5 Trillion Milestone: AI Boom Propels NVDA Stock to New Heights

Nvidia’s market value topped $5 trillion after shares rose nearly 3% to about $206 in late October, making it the world’s most valuable company. Q2 FY2025 revenue hit $46.74 billion, beating estimates, as demand for AI chips drove a 1,000% revenue surge in five years. Nvidia now controls about 80% of the global AI accelerator chip market. It recently announced a $100 billion partnership with OpenAI and a $1 billion investment in Nokia.
4 November 2025
···
Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma shares jumped about 135% to $10.77 on Nov. 4, 2025, after announcing a buyout by QOL Medical for $11 per share in cash. The $17 million deal, approved by both boards, is expected to close by year-end. Evoke’s only product is Gimoti, an FDA-approved nasal spray for diabetic gastroparesis. Q2 net sales rose 47% to $3.8 million, but the company remains unprofitable.
4 November 2025
··
Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis 2025: Animal Health Giant’s Latest Breakthroughs, Stock Outlook & Key Investor Insights

Zoetis reported 2024 revenue of $9.3 billion, up 9% from 2023, with gross margins near 72% and net profit margin around 29%. Shares traded at $130–$135 in November 2025, down from a 52-week high of $180. The company raised its dividend by 15% to $2.00 per share. Analysts’ average 12-month target is $188, though some issued downgrades in late 2025 amid slowing growth.
4 November 2025
··
Harley-Davidson Stock Roars on Earnings Beat – Is HOG a Buy Heading into 2026?

Harley-Davidson Stock Roars on Earnings Beat – Is HOG a Buy Heading into 2026?

Harley-Davidson stock rose nearly 2% to about $27.60 on Nov. 4, 2025, after reporting Q3 earnings far above expectations. Diluted EPS hit $3.10, nearly double forecasts, and revenue climbed 17% to $1.34 billion. Global retail unit sales fell 6% as demand softened, but premium touring models saw strong sales. Analyst views remain mixed, with Morgan Stanley downgrading the stock while others maintain buy ratings.
4 November 2025
··
Yum! Brands Stock on the Rise: Earnings Beat, Pizza Hut Shakeup & 2025 Outlook

Yum! Brands Stock on the Rise: Earnings Beat, Pizza Hut Shakeup & 2025 Outlook

Yum! Brands shares rose over 2% in pre-market trading Nov. 4 after Q3 earnings beat forecasts, with revenue up 8.4% to $1.98 billion and adjusted EPS at $1.58. CEO Chris Turner launched a strategic review of Pizza Hut, which posted its seventh straight sales decline and now accounts for just 11% of operating profit. Yum pays a $0.71 quarterly dividend and continues buybacks. Analysts set average price targets in the low $160s.
4 November 2025
·
Norwegian Cruise Line Stock Plunges Despite Record Quarter – Is NCLH Still Set to Sail High in 2025?

Norwegian Cruise Line Stock Plunges Despite Record Quarter – Is NCLH Still Set to Sail High in 2025?

Norwegian Cruise Line Holdings shares fell about 10% to $20 intraday on Nov. 4 after Q3 revenue missed estimates, despite raising full-year EPS guidance. The stock is down roughly 9% year-to-date, underperforming Carnival. Q3 adjusted EPS beat expectations, but free cash flow was negative due to new ship spending. Market cap stands at $10.1 billion, with heavy debt and no dividend.
4 November 2025
·
ADM Stock Plummets on Outlook Cut – Key Facts and What’s Next

ADM Stock Plummets on Outlook Cut – Key Facts and What’s Next

ADM shares fell about 10% to $54 on Nov. 4 after the company cut its 2025 profit forecast and missed Q3 revenue estimates. Adjusted Q3 earnings were $0.92 per share, above forecasts, but revenue of $20.37 billion missed expectations. The new full-year EPS outlook of $3.25–$3.50 is well below Wall Street estimates. Year-to-date, ADM stock remains up 19%.
4 November 2025
·
Uber Stock Skyrockets on Earnings Beat – Is the Rideshare Giant Set to Keep Surging?

Uber Stock Skyrockets on Earnings Beat – Is the Rideshare Giant Set to Keep Surging?

Uber shares closed at $99.72 on Nov. 3, just below record highs, before falling about 4% in pre-market trading after issuing softer Q4 guidance. Third-quarter revenue rose 20% to $13.5 billion, with adjusted EBITDA up 33% to $2.3 billion and net income boosted by a tax benefit to $6.6 billion. Uber expanded its partnership with Toast and acquired Segments.ai. Wall Street’s average 12-month price target is $110–112.
4 November 2025
··
Amazon’s $2.5 Billion Cloud Outage: How an AI Glitch Broke the Internet – Again

Amazon’s $2.5 Billion Cloud Outage: How an AI Glitch Broke the Internet – Again

Amazon Web Services suffered a 16-hour outage in late October 2025, disrupting over 2,500 companies and major apps including Fortnite, Snapchat, and Coinbase. Amazon traced the incident to a bug in automated DNS management in its US-East-1 region, which triggered cascading failures. Engineers restored service after manual intervention. The outage caused an estimated $2.5 billion in global losses.
4 November 2025
······
AI Darlings at Record Highs – Why Wall Street Fears a Frothy Stock Bubble

AI Darlings at Record Highs – Why Wall Street Fears a Frothy Stock Bubble

The S&P 500 hovered near record highs after October’s rally, but two-thirds of its stocks fell Monday even as the index edged up. Tech giants like Nvidia and Amazon, boosted by AI momentum, have driven most gains—Nvidia is up 55% this year, Palantir nearly 400%. Wall Street leaders warn valuations are stretched and a correction may be coming. Despite strong earnings, investor caution persists, with some stocks dropping after upbeat results.
4 November 2025
····
Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Palantir Technologies reported Q3 2025 revenue of nearly $1.2 billion, up 63% year-on-year, and raised full-year guidance to $4.4 billion. CEO Alex Karp declared Palantir “the first company to be completely anti-woke,” defended its work with ICE and Israel, and told critics to “get some popcorn.” Shares surged 200% in 2025 but fell 7% after earnings on valuation concerns.
4 November 2025
··
1 … 1,582 1,583 1,584 1,585 1,586 … 1,848

Stock Market Today

  • Revolution Medicines Price Target Raised by 11.57% to €116.43
    April 12, 2026, 2:18 AM EDT. Revolution Medicines (BIT:1RVMD) saw its average one-year price target increase by 11.57% to €116.43 per share from €104.36. Analyst targets range widely from €62.73 to €151.87. The new target price represents a potential gain of 39.44% over the latest closing price of €83.50. Institutional ownership has decreased by 10.18% to 188.7 million shares, with 391 funds reporting holdings, down 42.67% in the last quarter. Leading shareholders include Farallon Capital Management and Janus Henderson Group, both raising their portfolio allocations significantly. The shifts highlight mixed institutional sentiment despite the upward price forecast.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 12.04.2026

12 April 2026
Futu Holdings (FUTU) rose 10.2% in the past week but trades 13.4% below its January level. Shares closed at $154.50, while analysts estimate intrinsic value at $245.48. The company posted a 92.2% return over 12 months. Valuation models indicate earnings exceed risk costs, supporting long-term growth projections.
India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

India F-35 Deal Hits Pause: Lockheed Martin Says No Direct Talks, U.S. Door Still Open

11 April 2026
Lockheed Martin said it is not in direct talks with India over the F-35, clarifying that any approach must go through official U.S. and Indian channels under the Foreign Military Sales process. Indian officials confirmed no formal discussions on acquiring the F-35 have begun. India recently approved a $40 billion military upgrade, including other fighter jets, while Lockheed’s F-21 remains in a separate competition.
Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

Why SNOW Stock Is Falling Again: Snowflake Nears 52-Week Low as AI Worries Hit Software

11 April 2026
Snowflake shares fell 8.4% to $121.11 on Friday after an 11.7% drop Thursday, as investors sold off software stocks amid concerns over new AI tools from Anthropic and OpenAI. The stock now trades just above its 52-week low. The S&P 500 Software and Services Index is down 25.5% for the year. Snowflake reported fourth-quarter product revenue of $1.23 billion, up 30% from a year earlier.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 11:59 PM EDT DocuSign Stock Review: Is the 42% Yearly Drop a Buying Opportunity? April 11, 2026, 11:59 PM EDT. DocuSign (DOCU) shares have fallen 42.3% over the past year, raising questions about their value. Despite recent weakness, a Discounted Cash Flow (DCF) analysis suggests the stock is **68.1% undervalued**, with estimated intrinsic value around $134.42 versus a current price near $42.89. The DCF model projects growing free cash flows from $990 million in 2026 to $1.37 billion by 2029. Investors remain cautious amid evolving software spending trends
Go toTop